Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Acute myeloid leukaemia, drawn from the whole corpus: 116 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
TP53-mutant AML: no drug class has yet improved survival, so it is the priority for new mechanisms.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Targets · KRAS roadmap.
Older patients.
TP53-mutated and complex-karyotype AML: no class has improved survival; magrolimab (CD47) and eprenetapopt (p53 reactivator) both failed in phase 3.
Relapse after allogeneic transplant is the main way treatment fails; which maintenance (FLT3, menin, azacitidine) helps whom is unresolved.
Background: MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
Menin-inhibitor resistance through MEN1 mutations appears within months in a third of relapsing patients; combinations and next-generation inhibitors are needed.
Also on OnCo: Resistance atlas · Lines of therapy.
Infections and low blood counts early in venetoclax-based therapy are the main risk in the very old; optimal venetoclax duration is untested in randomised trials.
MRD thresholds and assays are not harmonised across labs, and CHIP-associated mutations confound NGS MRD.
Background: MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
Whether triplets (menin or FLT3 inhibitor + venetoclax + HMA) improve survival over doublets, and at what toxicity, awaits phase 3.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Access: rapid genomics within 72 hours and menin/FLT3 inhibitors are unavailable in most low- and middle-income settings.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 83 changes by month →When this page itself was last checked or edited.
With venetoclax in newly diagnosed unfit AML
Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)
7+3 plus midostaurin (ITD or TKD) or quizartinib (ITD only), consolidation with continued inhibitor, allogeneic transplant for most FLT3-ITD in CR1, post-transplant FLT3-inhibitor maintenance if MRD-positive. (NCCN Category 1 (midostaurin, quizartinib), ESMO-MCBS A (RATIFY))
ATRA + arsenic trioxide without chemotherapy for standard risk (cure >95%); ATRA + arsenic + idarubicin or gemtuzumab for high risk. Differentiation syndrome prophylaxis. (NCCN Category 1)
Marrow morphology, flow, karyotype/FISH, rapid FLT3/NPM1/IDH testing (results within days), NGS panel; ELN 2022 risk; fitness assessment. Menin-inhibitor and FLT3-inhibitor eligibility depends on these results. (NCCN Category 2A)